Incanthera Ltd develops pharmaceutical products for tumors. It develops cancer therapies, such as ICT01-2588, a vascular disrupting agent and drug delivery platform for lung and prostate cancer; and ICT03-Es5, a bioreductive anticancer agent for lung, liver, and breast cancer.
Incanthera Ltd
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttp://www.incanthera.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address76 King Street,,M2 4NHManchesterUnited Kingdom
76 King Street,,M2 4NH
Manchester
United Kingdom
Contact Number+44 161 8175005
+44 161 8175005
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/incanthera-limited” connections=”true” suffix=””]